“…METHODS: Biopsy-proved advanced pancreatic cancer patients who received systemic chemotherapy were enrolled after signed informed consent. CA19-9 and cfDNA in blood were measured before and after every two cycles of treatments, and the disease progression was monitored by computed tomography (CT) with 3-month interval. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Meanwhile, 37.2% and 45.2% of the respondents expressed moderate–severe anxiety before and after vaccination, respectively. Wilcoxon signed-rank test revealed that the drop in the level of stress from before- (median (IQR) = 5 (1–8)) to after vaccination (median (IQR) = 3 (1–7)) was statistically significant (z = −3.81, p = 0.001, r = 0.17) while the increase in anxiety was not. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Spearman's correlation and Kendall's tau‐b correlation were used to analyze the relationship between NODDI metrics and mJOA scores. Wilcoxon signed rank test was used to examine the changes in the NODDI and mJOA scores between the preoperative and 6‐month follow‐up stages. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…EUS findings considered were: focal mass echogenicity, loss of lobularity, distal atrophy, peripancreatic hypoechoic margins (PHM), pancreatic duct dilation, duct-penetrating sign (DPS), pancreatic/common bile duct thickened walls (PD/CBD-TW), and vessel infiltration (VI). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Descriptive statistics were used to express the results. Wilcoxon Signed‐Rank test was used to determine the statistical significance at p < 0.05. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We compared the splenic volume in those achieving a clinical benefit and those not achieving clinical benefit, using non-parametric Wilcoxon signed-rank test. Clinical benefit was defined as stable disease or partial response lasting for greater than 24 weeks. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Thus, focal uptake of [(18)F]PSMA-1007 outside its physiological distribution is not a categorical sign of metastasis and can arise from non-specific uptake of the ligand. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…While there was a significant difference between paired %MF measurements from baseline to post-pacing in experimental dogs (P = 0.019), there was no significant change in control dogs (P = 0.019 and P = 0.5, Wilcoxon signed rank tests). The median %MF for paced animals was significantly greater than that of non-paced dogs at the 5-week post-insertion time point (P = 0.009, Mann Whitney U test). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The phenotypic correlations were similar in direction (same sign) and lower than the corresponding genetic correlations. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The ability of root canal sealers to penetrate dentinal tubules cannot be considered a sign of better interfacial adaptation.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Participants read and signed an electronic informed consent before participating in this study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…TB‐DM patients were with higher the proportion of TB severity score ≥3, compared with TB‐NDM patients, but the distributions of drug susceptibility testing (DST) analysis were not significantly different between the two groups of patients. Remarkably, the sign of central shadow of pulmonary lobe distribution and cavity in TB‐DM group presented significantly higher rate than it in TB‐NDM group. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The only treatment‐related clinical sign was self‐limiting vomiting (in 2/8 treated animals) and the only treatment‐related clinical pathological changes seen were a slight decrease in serum albumin in one dog (2.6 g/dL; reference 2.7 to 3.9 g/dL) and total protein (5.1 g/dL; reference 5.5 to 7.7 g/dL). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The primary endpoint was change from baseline in total sign score (TSS) in crisaborole‐ or vehicle‐treated target lesions on day 15, and secondary endpoints included change from baseline in Investigator’s Static Global Assessment (ISGA) and pruritic assessments (Cohort 1: peak pruritus numeric rating scale [NRS]; Cohort 2: Itch Severity Scale Self‐Report and Caregiver‐Reported Itch Severity NRS) and incidence of treatment‐emergent adverse events (TEAEs). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Paired samples t-tests (and Related-Samples Wilcoxon Signed Rank Tests for non-normal distributions) detected statistically significant results for 10 of 12 measures, including reductions in pain (M = 4.54 to M = 3.54; p = .025; BPI), functional disability (M = 0.94 to M = 0.73, p = .032; HAQ-II), cognitive and physical dysfunction (M = 25.46 to M = 13.54, p < .001; CPFQ), depressive symptoms (M = 9.31 to M = 5.54, p = .003; PHQ-9), anxiety (M = 5.69 to M = 3.23, p = .005; GAD-7), insomnia (M = 11.62 to M = 17.32, p = .007; Note: higher scores on the SCI indicate less insomnia), stress-related eating (M = 75.46 to M = 84.54, p = .021; Note: higher scores on the EADES indicate less stress-related eating), along with significant increases in mindfulness (M = 62.54 to M = 67.85, p = .040; MAAS), mental wellness (M = 4.46 to M = 5.69; HERO), and well-being (M(d) = 8.00 to M(d) = 5.00, p = .004; WHO-5). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso